Clearmind Medicine Inc. Common Shares (CMND) - Total Assets
Based on the latest financial reports, Clearmind Medicine Inc. Common Shares (CMND) holds total assets worth $11.14 Million USD as of January 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CMND cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Clearmind Medicine Inc. Common Shares - Total Assets Trend (2014–2025)
This chart illustrates how Clearmind Medicine Inc. Common Shares's total assets have evolved over time, based on quarterly financial data. See Clearmind Medicine Inc. Common Shares (CMND) shareholders funds for net asset value and shareholders' equity analysis.
Clearmind Medicine Inc. Common Shares - Asset Composition Analysis
Current Asset Composition (October 2025)
Clearmind Medicine Inc. Common Shares's total assets of $11.14 Million consist of 97.8% current assets and 2.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 64.5% |
| Accounts Receivable | $322.28K | 5.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $97.36K | 1.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Clearmind Medicine Inc. Common Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Clearmind Medicine Inc. Common Shares worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clearmind Medicine Inc. Common Shares's current assets represent 97.8% of total assets in 2025, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 64.5% of total assets in 2025, up from 27.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 5.3% of total assets.
Clearmind Medicine Inc. Common Shares Competitors by Total Assets
Key competitors of Clearmind Medicine Inc. Common Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
Clearmind Medicine Inc. Common Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.79 | 1.72 | 7.56 |
| Quick Ratio | 3.79 | 1.72 | 7.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.11 Million | $3.97 Million | $165.06K |
Clearmind Medicine Inc. Common Shares - Advanced Valuation Insights
This section examines the relationship between Clearmind Medicine Inc. Common Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.75 |
| Latest Market Cap to Assets Ratio | 0.92 |
| Asset Growth Rate (YoY) | -39.8% |
| Total Assets | $6.08 Million |
| Market Capitalization | $5.61 Million USD |
Valuation Analysis
Near Book Valuation: The market values Clearmind Medicine Inc. Common Shares's assets close to their book value (0.92x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Clearmind Medicine Inc. Common Shares's assets decreased by 39.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Clearmind Medicine Inc. Common Shares (2014–2025)
The table below shows the annual total assets of Clearmind Medicine Inc. Common Shares from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-10-31 | $6.08 Million | -39.77% |
| 2024-10-31 | $10.10 Million | +69.65% |
| 2023-10-31 | $5.95 Million | +430.74% |
| 2022-10-31 | $1.12 Million | -73.05% |
| 2021-10-31 | $4.16 Million | +981.80% |
| 2020-10-31 | $384.81K | +184.04% |
| 2019-10-31 | $135.47K | -27.96% |
| 2018-10-31 | $188.06K | +86.86% |
| 2017-10-31 | $100.65K | +2241.17% |
| 2016-10-31 | $4.30K | +1492.22% |
| 2015-10-31 | $270.00 | -97.89% |
| 2014-10-31 | $12.79K | -- |
About Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It d… Read more